Background: Appropriately timed cessation of chemotherapy is integral to patient's quality of life. We evaluate the use of and associated factors with chemotherapy at the end of life.
introduction Appropriately timed cessation of chemotherapy is integral to patient's quality of life (QoL) and is recognised as a quality assurance factor in many medical oncology units. Chemotherapy cessation in the last 2 weeks of life has been included as a benchmark for improving clinical practice in Quality Oncology Practice Initiative (QOPIä) of the American Society of Clinical Oncology. Studies by Earle et al. [1] , using administrative data from health insurance claims to identify indicators for quality of end-of-life services for cancer patients, concluded that continuation of ongoing treatments very near to death was overly aggressive care. They determined that <10% of patients should receive chemotherapy in the last 14 days of life [2] .
A North American study utilising the Surveillance, Epidemiology and End Results (SEER) data on the use of palliative chemotherapy in the terminal phase of patients' lives found that of those patients who received palliative chemotherapy, 18.5% received chemotherapy in the last 2 weeks of life [3] . In Ontario, Canada, 16% of patients who had received chemotherapy in the last 6 months of their life continued to receive it in the last 2 weeks of life, while 4.2% of all terminal oncology patients received chemotherapy in the last 2 weeks of life [4] . Using administrative fee-for-service Medicare beneficiary databases from Massachusetts and California, the rate of continuation of chemotherapy in the last 4 weeks of life among patients aged >65 years was 9% [5] . This was higher in the setting of community oncology with rates up to 20% and 43%, respectively, for continuation of chemotherapy in the last 2 and 4 weeks in patients with advanced non-small-cell lung cancer (NSCLC) [6] . A Finnish study reported that 19.7% of advanced breast cancer patients continued with chemotherapy in the last month of life [7] . Rates may be higher for younger commercially insured patients, with the MarketScan MEDSTAT database reporting that 17.1% were treated within 2 weeks of death [8] . It appears that the use of chemotherapy near the end of life is increasing [3, 8] .
Factors associated with the use of chemotherapy at the end of life require further investigation. The Canadian study found female gender, cancer type [e.g. central nervous system (CNS) and prostate cancer], utilisation of home care, palliative care assessment and physician house calls to be significant factors associated with decreased chemotherapy utilisation at the end of life [4] . The SEER database study [8] found that elderly, female, non-white and unmarried patients were less likely to receive chemotherapy at the end of life. Patients who had initially presented with early-stage cancer and later relapsed, and those with a longer duration of illness, were less likely to be treated with chemotherapy near the end of life. Haematological malignancies were most strongly associated with aggressive original article *Correspondence to: Dr D. Adams, Macarthur Cancer Therapy Centre, Campbelltown Hospital, PO Box 149, Campbelltown, NSW 2560, Australia. Tel: +612-46344300; Fax: +612-46344350; E-mail: rada6283@bigpond.net.au chemotherapy care [8] . Furthermore, receiving care in a teaching hospital and living in an area with more teaching hospitals appear to predispose to more aggressive care [8] .
Emanuel et al. [5] found similar chemotherapy use among patients regardless of the relative chemosensitivity of their tumour type.
Here, we determine the proportion of patients with metastatic cancer who ever received palliative chemotherapy and the proportion of these who received chemotherapy within 2 and 4 weeks of death. Factors that may predict for commencement of palliative chemotherapy and for continuation of chemotherapy in the last 2 and 4 weeks of life were evaluated in patients with metastatic disease.
methods
This study used a retrospective cohort design. All patients who died of advanced cancer treated with palliative intent at Liverpool Cancer Therapy Centre and Macarthur Cancer Therapy Centre, Sydney, Australia, from April 2005 to March 2007 were identified from the electronic medical records of the LANTIS Oncology Management System. Both cancer centres are academic teaching oncology units with inpatient and home-based palliative care facilities. The data were acquired from the LANTIS electronic medical records that included all i.v., oral and intrathecal chemotherapy administered during this period. Additional demographic information was obtained from patient charts where required. Patients were excluded if the cancer diagnosis was a haematological malignancy, if they were not seen by the medical oncology service or if they were treated with adjuvant or curative intent.
Palliative chemotherapy was defined as chemotherapy treatment with noncurative intent. These are treatments that concentrate on reducing severity of the disease symptoms, rather than providing a cure. LANTIS has required fields that specify chemotherapy type such as curative, adjuvant and palliative intent. The records were reviewed to ascertain palliative intent.
The following information was collected for each patient: age at time of death, gender, country of birth (classified as Australian born or non-Australian born), treating medical oncologist (seven physicians), cancer type, number of lines of palliative chemotherapy and chemosensitivity of the tumour. Relative chemosensitive tumours were defined as tumours that have ‡30% response rate to typical first-line palliative chemotherapy [including breast cancer, colorectal cancer, small-cell lung cancer (SCLC), gestational trophoblastic disease (GTD) and ovarian cancer]. Relative chemoinsensitive tumours were defined as tumours that have £30% response rate to first-line palliative chemotherapy [including pancreatic cancer/cholangiocarcinoma, NSCLC, melanoma, hepatocellular carcinoma (HCC), renal cell carcinoma (RCC) and CNS tumour].
Approval for the study was obtained by the institutional review board of the hospital.
statistical analysis
Data were analysed using SPSS Version 15.0. The outcome variables were the commencement of palliative chemotherapy and continuation within the last 2 and 4 weeks of life. The influence of age, gender, country of birth, cancer types, number of lines of chemotherapy, chemosensitivity of the tumour and treating medical oncologist were determined using chi-square test. A P value of £0.05 denoted statistical significance. For each of the three outcome variables, statistically significant predictors in the univariate analyses were entered into a logistic regression model. The final model was derived using the backward selection method. Results of the logistic regression modelling are presented as odds ratios (ORs) and associated 95% confidence intervals (CIs).
results
We identified 747 patients who died with advanced cancer in the study period. The median age was 67 years (range 20-96) with 44% female and 56% male. Fifty per cent of patients were Australian born, while 46% were overseas born and 4% with unknown country of birth.
The following solid tumour types were represented: NSCLC 147 (19.7%), colorectal cancer 120 (16.1%), breast cancer 89 (11.9%), pancreatic cancer/cholangiocarcinoma 64 (8.6%), prostate cancer 49 (6.6%), cancer of unknown primary 45 (6%), gastro-oesophageal cancer 43 (5.8%), SCLC 30 (4%), CNS cancer 28 (3.7%), ovarian cancer 27 (3.6%), bladder cancer 26 (3.5%), head and neck cancer 21 (2.8%), HCC 15 (2%), melanoma 13 (1.8%), cervical cancer 8 (1%), RCC 7 (0.9%), sarcoma 5 (0.7%), endometrial cancer 5 (0.7%), smallbowel cancer 2 (0.3%), anal cancer 1 (0.1%), penile cancer 1 (0.1%) and GTD 1 (0.1%).
Of the 747 patients identified, 398 (53%) received palliative chemotherapy and 349 (47%) were treated with best supportive care alone. Thirty-two patients received chemotherapy in the last 2 weeks of life and 73 patients in the last 4 weeks of life. This represents 4% and 10% of patients who received chemotherapy in the last 2 and 4 weeks of life, respectively, among all patients who died of metastatic disease (n = 747), and 8% and 18%, respectively, among patients who received palliative chemotherapy at any time (n = 398).
Of the 398 patients who were commenced on palliative chemotherapy, 256 patients (64%) received one line of palliative chemotherapy, 75 patients (19%) two lines, 43 patients (11%) three lines, 17 patients (4%) four lines and seven patients (2%) five lines.
Factors found to influence commencement of palliative chemotherapy in patients with incurable cancer were younger age, female gender, cancer type (CNS tumours) and the chemosensitivity of the tumour (see Table 1 ). With multivariate analysis using a logistic regression model, age <67 years (OR 3.78, 95% CI 2.54-5.62), cancer type (CNS tumours OR 3.4 compared with NSCLC, 95% CI 1.25-9.22) and tumour chemosensitivity (OR 3.51, 95% CI 1.42-8.72) remained significant predictors (see Table 2 ).
The only significant predictor found for continuation of palliative chemotherapy in the last 4 weeks of life was the individual treating medical oncologist (see Table 3 ).
There were no factors that predicted for continuation of palliative chemotherapy in the last 2 weeks of patient's life (see Table 3 ).
discussion
Chemotherapy remains the mainstay of treatment of patients with advanced malignancy in the developed countries. Toxic side-effects that significantly reduce patients' QoL and increase fatigue and anxiety are unacceptable when the aim of treatment is palliation of symptoms. Therefore, appropriately timed cessation of chemotherapy is critical. However, in most cases, use of chemotherapy in the last few weeks of a patient's life may indicate poor clinical judgement.
Our study is the first to describe the pattern of palliative chemotherapy utilisation and continuation of chemotherapy until the end of life in an Australian teaching hospital setting. We found that slightly more than half (53%) of our patients with metastatic disease commenced palliative chemotherapy; with younger age, tumour type and relative chemosensitivity of the tumour being positive predictors for receiving chemotherapy.
The use of palliative chemotherapy in our study was 8% in the last 2 weeks of life among all patients who had been commenced on chemotherapy, compared with up to 18.5% in North America. Possible explanations to account for the lower rate in the Australian population include access to free quality palliative care services for all patients and the exclusion of patients with haematological malignancies in this study (compared with inclusion of 10% haematological malignancy in the Canadian study [4] ), which have been shown to be associated with more aggressive care [8] .
Interestingly, the only variable that showed statistical significance as a predictor for continuation of chemotherapy in the last 4 weeks of life was the treating medical oncologist (P < 0.05). Although not statistically significant, this was a trend for predicting continuation of chemotherapy in the last 2 weeks of life (P = 0.06).
There are multiple reasons why patients are continued on potentially futile treatment at the end of life. This is the first study to find that the individual treating oncologist played a role in continuation of chemotherapy in the last few weeks of life. All medical oncologists involved treat patients with a variety of tumour groups, so tumour site is unlikely to account for this and was not significant on analysis. The physician-patient relationship is a complex one and often determines the final therapeutic approach. Assessing a patient's prognosis is a difficult art, but provides important information that may be crucial for the doctor, patients and caregivers to make informed treatment decisions such as when to cease chemotherapy and transit to symptom control only. Many patients and caregivers have indicated that they want this information and that it impacts on their treatment decisions as well as personal planning. A systematic review of 12 studies showed that clinicians overestimate prognosis by 27% [9] . Prognostication tools such as the validated Palliative Prognostic Score may assist and have been shown to be more accurate than clinician estimates alone. Whether use of such scores could assist appropriate timing of cessation of chemotherapy is an area for further research [10] .
Another possible explanation for the continuation of chemotherapy at the end of life is that recommending a new course of chemotherapy to patients is often an easier option than discussing cessation of chemotherapy and transition to palliative care with them and their caregivers. It is ironic that in both the United States and Australia, oncologists receive 
Annals of Oncology
original article financial reimbursement for chemotherapy delivery but little or no reimbursement for the time-consuming and emotionally difficult process of family conferences or end-of-life discussions.
Patient-related factors that may contribute to patients receiving futile chemotherapy at the end of life include personality trait of the patient and/or the family in not wanting to give up a hope of a cure. It is well established that patients with cancer are often willing to endure substantial side-effects for a remote chance at small prolongations in life [5, 11] . Chemotherapy may also give the patient the sense of 'actively fighting' and a sense of control over their disease. A 'trial' of chemotherapy may give patients and family extra time to adjust to the diagnosis and prognosis. Conversely, it may delay acceptance of their preterminal condition and deny the patient and family a chance to prepare for their death or make adjustment more difficult for the family when the patient dies despite being on therapy. Although there are a lot of decision aids to help patients make decisions with regard to treatment of early-stage cancers, there is a comparative lack of decision aids in the metastatic setting to assist patients with the difficult task of weighing up the risks and benefits of stopping chemotherapy towards the end of life [12] .
As highlighted by Barbera et al. [4] , there are occasions when chemotherapy treatment near the end of life is appropriate. We acknowledge that unexpected deaths will occur in patients with metastatic disease due to either complications of the cancer or treatment such as pulmonary emboli or neutropaenic sepsis secondary to chemotherapy. There are also occasions where patients are quite unwell but where there is a reasonable chance of response and improvement from chemotherapy, e.g. in patients with SCLC.
The outcome variables used in this study are by no means the only indicators for quality end-of-life care. Other validated indicators used in the literature include [1, 2] intensive care unit admissions, emergency department visits, commencement of new anticancer therapies very near death, inpatient hospital admissions and underuse of hospice services. Prospective evaluations using those indicators to examine our health provision would be useful.
The major limitation of this study is that it is retrospective and therefore reliant on the accuracy of the hospital records. The electronic capture of chemotherapy use in our electronic record system LANTIS minimises such errors, but the recording of out-of-hospital deaths is reliant on them being reported by community palliative care teams, families and hospice. It was not feasible to check these data against a statewide death registry, so there is a potential for underestimation of deaths. Other potential factors influencing utilisation of palliative chemotherapy such as performance status, patient symptoms and QoL were not included in the analysis in this study as they could not be accurately collected with this retrospective design.
Just as underutilisation of treatments of known efficacy has been identified as poor quality care, studies such as ours reflect possible overutilisation of treatments of doubtful effectiveness original article Annals of Oncology or at inappropriate times. Such overuse is likely to increase with the emerging use of less toxic targeted therapies, which may delay appropriate transition to palliative care and increase the financial burden to the patient and/or the health system.
Ongoing monitoring of practice initiatives should therefore be encouraged and methods to assist physicians and their patients decide when and why therapy should be ceased need to be explored further.
references
